FDA’s Center for Drug Evaluation and Research launches new acceleration program ARC (Cell and Gene Therapy Catapult – Regulatory Round-up – May 2022)
The FDA’s Center for Drug Evaluation and Research (CDER) announced on the 10th of May 2022 the launch of the new Accelerating Rare disease Cures (ARC) Program harnesses CDER’s collective expertise and activities to provide strategic overview and coordination of CDER’s rare disease activities.
CDER’s ARC Program drives scientific and regulatory innovation and engagement to accelerate the availability of treatments for patients with rare diseases.
CDER’s ARC Program is governed by leadership from across CDER’s Office of the Center Director, Office of New Drugs, and the Office of Translational Sciences. The program is managed by CDER’s Rare Diseases Team.
See all of Catapult’s Regulatory Round-up for May 2022 here.
Published on the 6th of June 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (3 août 2022). FDA’s Center for Drug Evaluation and Research launches new acceleration program ARC (Cell and Gene Therapy Catapult – Regulatory Round-up – May 2022). ELSIBI. Consulté le 7 novembre 2026 à l’adresse https://doi.org/10.58079/o61n





